JOP20200100A1 - مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 - Google Patents

مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3

Info

Publication number
JOP20200100A1
JOP20200100A1 JOP/2020/0100A JOP20200100A JOP20200100A1 JO P20200100 A1 JOP20200100 A1 JO P20200100A1 JO P20200100 A JOP20200100 A JO P20200100A JO P20200100 A1 JOP20200100 A1 JO P20200100A1
Authority
JO
Jordan
Prior art keywords
pyrrolo
pyrimidine
compounds
inhibitors
dione derivatives
Prior art date
Application number
JOP/2020/0100A
Other languages
English (en)
Inventor
Nagel Jens
Neuhaus Roland
Martin Fischer Oliver
Br?Uer Nico
Siebeneicher Holger
Lindsay Carr James
Anne Parrott Shelley
Koppitz Marcus
Rotgeri Andrea
James Davenport Adam
Pook Elisabeth
James Townsend Robert
Connelly Ursinyova Nina
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of JOP20200100A1 publication Critical patent/JOP20200100A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بيرازولو-بيرولو-بيريميدين-ديون (PPPD) مستبدلة من الصيغة العامة (I): حيث يكون R1، R2 و R3 كما تم تعريفهم هنا، ويتعلق بطرق لتحضير المركبات المذكورة، وتراكيب صيدلية وتوليفات تشتمل على المركبات المذكورة واستخدام المركبات المذكورة لتصنيع تراكيب صيدلية للمعالجة أو الوقاية من أمراض، وبصورة محددة الاضطرابات عصبية المنشأ، كعامل مفرد أو في توليفة مع مكونات فعالة أخرى.
JOP/2020/0100A 2017-10-27 2018-10-18 مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3 JOP20200100A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27
PCT/EP2018/078567 WO2019081343A1 (en) 2017-10-27 2018-10-18 NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

Publications (1)

Publication Number Publication Date
JOP20200100A1 true JOP20200100A1 (ar) 2020-05-06

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0100A JOP20200100A1 (ar) 2017-10-27 2018-10-18 مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3

Country Status (25)

Country Link
US (1) US11319324B2 (ar)
EP (1) EP3700907B1 (ar)
JP (1) JP7250011B2 (ar)
KR (1) KR20200078567A (ar)
CN (1) CN111527090B (ar)
AU (1) AU2018354777A1 (ar)
BR (1) BR112020008122B1 (ar)
CA (1) CA3080249A1 (ar)
CL (1) CL2020001107A1 (ar)
CO (1) CO2020005065A2 (ar)
CR (1) CR20200174A (ar)
CU (1) CU20200038A7 (ar)
DK (1) DK3700907T3 (ar)
DO (1) DOP2020000100A (ar)
EA (1) EA202091003A1 (ar)
EC (1) ECSP20023626A (ar)
ES (1) ES2914377T3 (ar)
IL (1) IL274036A (ar)
JO (1) JOP20200100A1 (ar)
MA (1) MA50439A (ar)
MX (1) MX2020004981A (ar)
NI (1) NI202000031A (ar)
PH (1) PH12020550494A1 (ar)
SG (1) SG11202003662XA (ar)
WO (1) WO2019081343A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311A (zh) * 2019-11-01 2021-05-11 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
US20230118497A1 (en) * 2019-12-10 2023-04-20 Shanghai Hansoh Biomedical Co., Ltd. Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132424A (en) 1988-07-21 1992-07-21 The Upjohn Company Pyrazolo-pyrrolo-pyrimidine-diones
CA2206080A1 (en) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesic composition_of pryazolo{1,5-a}pyrimidine derivatives
KR20020050257A (ko) 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
EP2044074A2 (en) 2006-06-23 2009-04-08 Incyte Corporation Purinone derivatives as hm74a agonists
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JP6133291B2 (ja) * 2011-08-12 2017-05-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピラゾロ［３，４−ｃ］ピリジン化合物と使用方法
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
ES2638179T3 (es) * 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos

Also Published As

Publication number Publication date
DOP2020000100A (es) 2020-09-15
CU20200038A7 (es) 2021-03-11
IL274036A (en) 2020-06-30
CL2020001107A1 (es) 2020-10-23
ECSP20023626A (es) 2020-06-30
MA50439A (fr) 2021-05-19
JP7250011B2 (ja) 2023-03-31
EA202091003A1 (ru) 2020-09-11
CR20200174A (es) 2020-06-26
ES2914377T3 (es) 2022-06-10
EP3700907A1 (en) 2020-09-02
PH12020550494A1 (en) 2021-01-11
US11319324B2 (en) 2022-05-03
CA3080249A1 (en) 2019-05-02
WO2019081343A1 (en) 2019-05-02
JP2021500380A (ja) 2021-01-07
CO2020005065A2 (es) 2020-05-29
BR112020008122B1 (pt) 2022-11-01
NI202000031A (es) 2020-08-28
SG11202003662XA (en) 2020-05-28
KR20200078567A (ko) 2020-07-01
BR112020008122A2 (pt) 2020-11-03
DK3700907T3 (da) 2022-05-30
CN111527090A (zh) 2020-08-11
CN111527090B (zh) 2023-05-26
AU2018354777A1 (en) 2020-04-16
US20210317128A1 (en) 2021-10-14
EP3700907B1 (en) 2022-03-09
MX2020004981A (es) 2020-08-24

Similar Documents

Publication Publication Date Title
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
PH12016501581A1 (en) Benzimidazol-2-amines as midh1 inhibitors
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
PH12019502851A1 (en) New azaquinoline derivatives
PH12016501807A1 (en) Novel compounds
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
PH12020500134A1 (en) Dihydrooxadiazinones
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
PH12016501932A1 (en) Amido-substituted azole compounds
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
MA39762A (fr) Nouveaux composés